Session » Biology and Pathology of Bone and Joint: Cartilage, Synovium and Osteoarthritis

Meeting: 2014 ACR/ARHP Annual Meeting

Abstract Number: 1001

Fibroblast-like Synoviocytes Inhibit Wnt Signaling Pathway By Secreting Dockcop-1

Abstract Number: 1002

Global Transcriptome Analysis in Osteoarthritic Cartilage Reveals Significant Differential Gene Expression and Associations with Histologic Disease Progression

Abstract Number: 1003

Proteomic Analysis of Connexin 43 Reveals Novel Interactors Related to Osteoarthritis

Abstract Number: 1004

Elevated Levels of BMP2 Compensate for Loss of TGF-Beta in Articular Cartilage during Experimental Osteoarthritis

Abstract Number: 1005

Histone Lysine Demethylase KDM6A Mediates Joint Destruction in Osteoarthritic Knees By Epigenetic Disturbance of SOX9 Promoter and Histone H3K27

Abstract Number: 1006

Interleukin-4 As Promising, Anti-Inflammatory Transgene for Gene Therapeutic Application in Joint Diseases

Abstract Number: 1007

Markedly Increased Mesenchymal Stem Cell Activity in MRI Bone Marrow Lesions Compared with Non-Involved Bone in Osteoarthritic Hips

Abstract Number: 1008

Autophagy Activation Protects from Mitochondrial Dysfunction in Human Chondrocytes

Abstract Number: 1009

Regeneration of Articular Cartilage in Situ with Bone Marrow-Derived Mesenchymal Stem Cells

Abstract Number: 1010

Catecholaminergic-to-Cholinergic Transition of Sympathetic Nerve Fibers in Arthritis and in a Co-Culture System of Sympathetic Ganglia in Vitro

Abstract Number: 1011

Fibroblast Growth Factor-2 and Its Receptor Antagonists in Osteoarthritis

Abstract Number: 1012

Role of High Glucose Environment on Chondrocyte Activation and Characterization of Diabetic Osteoarthritic Cartilage: Toward Pathophysiological Delineation of Diabetes Mellitus-Related Osteoarthritis

Abstract Number: 1013

Mitochondrial Function Is Impaired in Human Knee Osteoarthritic (OA) Chondrocytes and Improved By Pharmacologic AMPK Activation Via SIRT1 and PGC-1α

Abstract Number: 1014

Harpagide, a Low Molecular Weight Natural Product, Suppresses IL-1â-Induced IL-6 Expression By Blocking the Activation of p38 MAPK and Transcription Factors CEBPâ and AP-1 in Primary Human Osteoarthritis Chondrocytes

Abstract Number: 1015

Mir-9/MCPIP1 Axis Mediated Regulation of IL-6 Expression in Osteoarthritis Chondrocytes

Abstract Number: 1016

Reduced Expression of Circadian Rhythm Genes in Human Osteoarthritis Cartilage: NR1D1 Suppression Alters Chondrocyte Response to IL-1β Stimulation

Abstract Number: 1017

BMP9-Induced pSmad1/5/8 Signaling and Chondrocyte Hypertrophy Are Effectively Inhibited By TGFβ1

Abstract Number: 1018

Monolayer Culture Induced the Expression of Zyxin-Related Protein 1 (ZRP-1), α_vβ₃integrin Complex and Leptin in Human Articular Chondrocytes

Abstract Number: 1019

Targeting the Bone-Driven Metabolic OA Phenotype By a Novel Dual Amylin Calcitonin Receptor Agonist, KBP-056

Abstract Number: 1020

Changes in Peripheral Blood Immune Cell Composition in Osteoarthritis

Abstract Number: 1021

Transthyretin and Amyloid in Cartilage Aging and Osteoarthritis

Abstract Number: 1022

Fibroblast-like Synovial Cells and Monocytes Team up in the Organization and the Dynamic Modelling of the Synovial Tissue

Abstract Number: 1023

Chronic PTHrP Treatment Promotes Hypertrophic Differentiation and Inflammatory Gene Expression in Chondrocytes

Abstract Number: 1024

Racial Differences in Biochemical Knee Cartilage Composition Between African American and Caucasian American Women with MR-Based T2 Relaxation Time Measurements – Data from the Osteoarthritis Initiative

Abstract Number: 1025

Leptin Production By Osteoarthritis Synovial Fibroblasts: Stimulation By Glucocorticoids and Mineralocorticoids through the Glucocorticoid Receptor and GILZ (Glucocorticoid-Induced Leucine Zipper) Protein

Abstract Number: 1026

Monosodium Urate Monohydrate Crystals Induces the Expression of Ihh and MMP-13 in ATDC5 Cells: Implications in Osteoarthritis (OA) Development.

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.